Progyny, Inc. (PGNY) Gross Margin
- Gross margin · 12 months: Value 24.57%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 24.57% | Gross profit / revenue. Period ending 2026-06-30. $322.09M ÷ $1.31B × 100 ≈ 24.57% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 322.09M USD | Gross Profit |
| Revenue | 1.31B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 988.68M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $322.09M | $1.31B | $988.68M | 24.57% |
| 2026-03-31 | $311.76M | $1.29B | $981.37M | 24.11% |
| 2025-12-31 | $304.48M | $1.29B | $984.18M | 23.63% |
| 2025-09-30 | $291.04M | $1.27B | $977.65M | 22.94% |
| 2025-06-30 | $277.44M | $1.24B | $964.52M | 22.34% |
| 2025-03-31 | $266.75M | $1.21B | $946.43M | 21.99% |
| 2024-12-31 | $253.36M | $1.17B | $913.86M | 21.71% |
| 2024-09-30 | $246.82M | (m) | $891.90M | (m) |
| 2024-06-30 | $250.21M | (m) | $882.79M | (m) |
| 2024-03-31 | $242.56M | (m) | $865.72M | (m) |
| 2023-12-31 | $238.80M | $1.09B | $849.80M | 21.94% |
| 2023-09-30 | $226.40M | (m) | $806.58M | (m) |
| 2023-06-30 | $209.77M | (m) | $747.69M | (m) |
| 2023-03-31 | $193.02M | (m) | $680.07M | (m) |
| 2022-12-31 | $167.32M | $786.91M | $619.59M | 21.26% |
| 2022-09-30 | $147.95M | (m) | $552.20M | (m) |
| 2022-06-30 | $130.44M | (m) | $486.62M | (m) |
| 2022-03-31 | $116.18M | (m) | $434.53M | (m) |
| 2021-12-31 | $112.14M | (m) | $388.49M | (m) |
| 2021-09-30 | $107.69M | (m) | $365.68M | (m) |
| 2021-06-30 | $100.03M | (m) | $349.98M | (m) |
| 2021-03-31 | $82.36M | (m) | $303.60M | (m) |
| 2020-12-31 | $70.06M | (m) | $274.80M | (m) |
| 2020-09-30 | $61.16M | (m) | $248.52M | (m) |
| 2020-06-30 | $52.65M | (m) | $219.30M | (m) |
| 2020-03-31 | $52.14M | (m) | $211.37M | (m) |
| 2019-12-31 | $45.51M | (m) | $184.18M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | $31.88M | (m) | $128.47M | (m) |
| 2019-03-31 | $25.46M | (m) | $104.88M | (m) |
| 2018-12-31 | $19.43M | (m) | $85.97M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $7.40M | (m) | $41.18M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |